ESMO Asia 2025
Gene Solutions Satellite
Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025
Gene Solutions Satellite
Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025
Gene Solutions Satellite
Symposium
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant
Gene Solutions Spotlights Genomic Innovations at IASLC Asia Conference on Lung Cancer (ACLC) 2025
Ho Chi Minh City, October 2025 – Gene Solutions proudly participated as a sponsor at the IASLC Asia Conference on Lung Cancer (ACLC) 2025, held in Ho Chi Minh City
EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION
During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention
Hoan My Medical Group and Gene Solutions Sign Strategic Partnership: Expanding Access to International-Standard Genetic Testing
Ho Chi Minh City, October 15, 2025 – Hoan My Medical Group and Gene Solutions held a strategic partnership signing ceremony, attended by Ms. Huynh Bich Lien, Chief Executive Officer
Gene Solutions Showcases MRD and Multi-Omics Advances at Singapore Society of Oncology Annual Scientific Meeting 2025
Gene Solutions hosted a landmark symposium titled “Advancing Precision Oncology: Molecular Residual Disease (MRD) and Multi-Omics in Solid Tumors” at the Singapore Society of Oncology (SSO) Annual Scientific Meeting, held
Clinical Case: Outsmarting Breast Cancer with Multi-Omics ctDNA
Overview Breast cancer is the second most common cancer worldwide, accounting for more than 600,000 deaths annually (1). Despite remarkable advances in early detection and treatment—leading to a 99% survival
CAP-Accredited Laboratory
Gene Solutions uniquely operates 2 CAP-accredited laboratories specializing in next-generation sequencing (NGS), within a network of 7 NGS laboratories in Asia.
Gene Solutions joins an esteemed group of laboratories worldwide. This rigorous process ensures that we not only meet but exceed the highest standards of care, ultimately delivering the best possible outcomes for our patients.
Gene Solutions Genomics Singapore Laboratory CAP#9709518
